Ryohei Katayama
0000-0001-7394-895X
5 papers found
Refreshing results…
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
Missing publications? Search for publications with a matching author name.